文献速递白血病造血干细胞移植与细胞治疗

成人T细胞急性淋巴细胞白血病中IL7R通路突变患者应答缓慢且不获益于异基因造血干细胞移植

Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.
PubMed 文献 · Leukemia · 2020-01-28

该研究基于GRAALL2003/2005方案纳入的200例成人T-ALL患者,采用二代测序检测IL7R/JAK1/JAK3/STAT5B突变。结果显示IL7Rp突变频率为28%,多见于未成熟/早期T细胞前体(ETP)-ALL,与NOTCH通路、PHF6及PRC2组分突变相关。IL7Rp突变患者为慢应答者,第8天骨髓M2/M3比例高(p=0.002)、6周MRD阳性率高(p=0.008),但12周MRD2无差异;在删失异基因HSCT后无不良预后,时间依赖分析显示HSCT对IL7Rp突变患者无获益,而对野生型患者明显获益。

要点

  • IL7Rp突变在成人T-ALL中发生率为28%,尤其富集于ETP-ALL。
  • IL7Rp突变者诱导应答慢:第8天骨髓M2/M3比例高、6周MRD阳性率高。
  • IL7Rp突变患者不获益于异基因HSCT,而野生型患者明显获益。

核心结论

  • IL7Rp突变定义了一组慢应答T-ALL亚群,其获益于诱导后化疗方案但不获益于异基因HSCT。
  • 提前知晓IL7Rp突变状态可能影响HSCT决策并有助于指导治疗降级。

研究设计与样本

  • 研究纳入GRAALL2003/2005方案中的200例成人T-ALL患者,采用二代测序检测IL7R/JAK1/JAK3/STAT5B突变。

主要发现

  • IL7Rp突变在成人T-ALL中频率为28%,尤其在未成熟/ETP-ALL中多见。
  • IL7Rp突变与NOTCH通路、PHF6及PRC2组分突变相关,但与K/NRAS突变无关。
  • IL7Rp突变者第8天骨髓M2/M3比例高于野生型(p=0.002),6周MRD阳性率更高(p=0.008),但12周MRD2阳性率无差异。
  • 删失HSCT后未见不良预后;时间依赖分析中HSCT对IL7Rp突变患者无获益,对野生型患者明显获益。

临床怎么用

  • 对成人T-ALL患者可考虑检测IL7Rp突变状态以识别慢应答亚群。
  • IL7Rp突变患者可能不适合将异基因HSCT作为强化治疗策略,可考虑诱导后化疗及治疗降级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognostic value of IL7-receptor pathway (IL7Rp) mutations in T-cell acute lymphoblastic leukemia (T-ALL) remains unclear. We performed a comprehensive study of 200 adult patients with T-ALL included in the GRAALL2003/2005 protocols to address the clinical significance of IL7Rp mutations. Next-generation sequencing of the IL7Rp (IL7R/JAK1/JAK3/STAT5B) revealed that IL7Rp mutations were frequent in adult T-ALL (28%) particularly in immature/early T-cell progenitor (ETP)-ALL. They were associated with mutations of NOTCH-pathway, PHF6, and PRC2 components but not with K/NRAS. IL7Rp mutated (IL7Rpmut) T-ALL were slow-responders, with a high rate of M2/M3 day-8 marrow compared with IL7Rp non-mutated (IL7RpWT) T-ALL (p = 0.002) and minimal residual disease positivity at 6-weeks (MRD1) (p = 0.008) but no difference in MRD2 positivity at 12-weeks. Despite this, no adverse prognosis was evidenced when censored for allogeneic hematopoietic stem cell transplantation (HSCT). In time-dependent analysis, HSCT did not benefit IL7Rpmut patients whereas it was of marked benefit to IL7RpWT cases. IL7Rp-mutations identify a subgroup of slow-responder T-ALLs which benefit from post-induction chemotherapy regimens but not from HSCT. Our data suggest that prior knowledge of the mutation status of IL7Rp may influence HSCT decision and help to guide therapy reduction.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Kim R, Boissel N, Touzart A, et al. Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. Leukemia. 2020. PMID: 31992840. doi:10.1038/s41375-019-0685-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。